Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment

Pain

Volumn 155, Issue 3, 2014, Pages 457-460

  Dworkin, Robert H ^a   McDermott, Michael P ^a   Farrar, John T ^b   O'Connor, Alec B ^a   Senn, Stephen ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Genotyping; Mechanism based treatment; Phenotyping; Treatment response; Treatment by patient interaction

Indexed keywords

ANALGESIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DRUG EFFICACY; GENOTYPE; HUMAN; NOCICEPTION; PAIN; PAIN ASSESSMENT; PARALLEL DESIGN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT RESPONSE;

GENOTYPING; MECHANISM-BASED TREATMENT; PHENOTYPING; TREATMENT RESPONSE; TREATMENT-BY-PATIENT INTERACTION;

ANALGESICS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PAIN; PHENOTYPE; TREATMENT OUTCOME;

EID: 84894270866     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.09.019     Document Type: Review

References (39)

1. N. Attal, D. Bouhassira, R. Baron, J. Dostrovsky, R.H. Dworkin, N. Finnerup, G. Gourlay, M. Haanpaa, S. Raja, A.S.C. Rice, D. Simpson, R.D. Treede, and C.D. Wells Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 15 2011 441 443
2. R. Baron, M. Förster, and A. Binder Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach Lancet Neurol 11 2012 999 1005
3. M.G. Byas-Smith, M.B. Max, J. Muir, and A. Kingman Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design PAIN® 60 1995 267 274
4. P. Croft, R. Froud, and A.M. Lewis Dropouts and sub-groups: statistics can help but not cure PAIN® 151 2010 563 564
5. Department of Health and Human Services, U.S. Food and Drug Administration. Enrichment strategies for clinical trials to support approval of human drugs and biological products: Draft guidance, < http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf >; 2012 [accessed 23.08.2013].
6. R.A. Dionne, L. Bartoshuk, J. Mogil, and J. Witter Individual responder analyses for pain: does one pain scale fit all? Trends Pharmacol Sci 26 2005 125 130 (Pubitemid 40313591)
7. J.T. Farrar, J. Messina, F. Xie, and R.K. Portenoy A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain Pain Med 11 2010 1313 1327
8. J.T. Farrar, J.P. Young Jr, L. LaMoreaux, J.L. Werth, and R.M. Poole Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale PAIN® 94 2001 149 158 (Pubitemid 33016608)
9. S. Fries, T. Grosser, T.S. Price, J.A. Lawson, S. Kapoor, S. Demarco, M.T. Pletcher, T. Wiltshire, and G. Fitzgerald Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 Gastroenterology 130 2006 55 64 (Pubitemid 43049835)
10. I. Gilron, J.M. Bailey, D. Tu, R.R. Holden, A.C. Jackson, and R.L. Houlden Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial Lancet 374 2009 1252 1261
11. I. Gilron, J.M. Bailey, D. Tu, R.R. Holden, D.F. Weaver, and R.L. Houlden Morphine, gabapentin, or their combination for neuropathic pain N Engl J Med 352 2005 1324 1334 (Pubitemid 40411499)
12. T.W. Ho, M. Backonja, J. Maa, H. Leibensperger, S. Froman, and M. Polydefkis Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies PAIN® 141 2009 19 24
13. W. Kalow, B.K. Tang, and L. Endrenyi Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research Pharmacogenetics 8 1998 283 289 (Pubitemid 28372321)
14. T.J. Kaptchuk, J.M. Kelley, A. Deykin, P.M. Wayne, L.C. Lasagna, I.O. Epstein, I. Kirsch, and M.E. Wechsler Do "placebo responders" exist? Contemp Clin Trials 29 2008 587 595
15. J.M. Kelley, and T.J. Kaptchuk Group analysis versus individual response: the inferential limits of randomized controlled trials Contemp Clin Trials 31 2010 423 428
16. C.D. King, B. Goodin, T.L. Glover, J.L. Riley, W. Hou, R. Staud, and R.B. Fillingim Is the pain-reducing effect of opioid medication reliable? A psychophysical study of morphine and pentazocine analgesia PAIN® 154 2013 476 483
17. R.L. Kravitz, N. Duanb, and J. Braslow Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages Milbank Q 82 2004 661 687 (Pubitemid 40143102)
18. J.A. Lewis Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?' Stat Med 28 2009 3213 3214
19. J. Lötsch, and G. Geisslinger Current evidence for a genetic modulation of the response to analgesics PAIN® 121 2006 1 5 (Pubitemid 43261625)
20. M.B. Max Towards physiologically based treatment of patients with neuropathic pain PAIN® 42 1990 131 133 (Pubitemid 20258897)
21. J.S. Mogil Pain genetics: past, present and future Trends Genet 28 2012 258 266
22. Moore RA. What works for whom? Determining the efficacy and harm of treatments for pain. PAIN®, 2013;154S1:S77-S86.
23. R.A. Moore, S.S. Smugar, H. Wang, P.M. Peloso, and A. Gammaitoni Numbers-needed-to-treat analyses: do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials PAIN® 151 2010 592 597
24. S.N. Raja, J.A. Haythornthwaite, M. Pappagallo, M.R. Clark, T.G. Travison, S. Sabeen, R.M. Royall, and M.B. Max Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial Neurology 59 2002 1015 1021
25. R.L. Rauck, M. Tark, E. Reyes, T.G. Hayes, A.J. Bartkowiak, D. Hassman, S. Nalamachu, R. Derrick, and J. Howell Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2009 2877 2885
26. R. Rolke, R. Baron, C. Maier, T.R. Tölle, R.-D. Treede, A. Beyer, A. Binder, N. Birbaumer, F. Birklein, I.C. Bötefür, S. Braune, H. Flor, V. Huge, R. Klug, G.B. Landwehrmeyer, W. Magerl, C. Maihöfner, C. Rolko, C. Schaub, A. Scherens, T. Sprenger, M. Valet, and B. Wasserka Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values PAIN® 123 2006 231 243
27. C.N. Sang, S. Booher, I. Gilron, S. Parada, and M.B. Max Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials Anesthesiology 96 2002 1053 1061 (Pubitemid 34462564)
28. J. Scholz, R.J. Mannion, D.E. Hord, R.S. Griffin, B. Rawal, H. Zheng, D. Scoffings, A. Phillips, J. Guo, R.J.C. Laing, S. Abdi, I. Decosterd, and C.J. Woolf A novel tool for the assessment of pain: validation in low back pain PLoS Med 6 2009 e1000047
29. S. Senn Statistical issues in drug development 1997 Chichester UK, Wiley
30. S. Senn Testing for individual and population equivalence based on the proportion of similar responses Stat Med 16 1998 1301 1306
31. S. Senn Applying results of randomized trials to patients: N of 1 trials are needed Br Med J 317 1998 537
32. S. Senn Individual therapy: new dawn or false dawn? Drug Inf J 35 2001 1479 1494 (Pubitemid 34563440)
33. S. Senn Author's reply to Walter and Guyatt Drug Inf J 37 2003 7 10
34. S. Senn Individual response to treatment: is it a valid assumption? Br Med J 329 2004 966 968 (Pubitemid 39422915)
35. S. Senn Added values: controversies concerning randomization and additivity in clinical trials Stat Med 23 2004 3729 3753 (Pubitemid 40074074)
36. S. Senn Statistical issues in drug development 2nd ed. 2007 Chichester UK, Wiley
37. S. Senn, and S. Julious Measurement in clinical trials: a neglected issue for statisticians? Stat Med 28 2009 3189 3209
38. C.J. Woolf, G.J. Bennett, M. Doherty, R. Dubner, B. Kidd, M. Koltzenburg, R. Lipton, J.D. Loeser, R. Payne, and E. Torebjork Towards a mechanism-based classification of pain? PAIN® 77 1998 227 229 (Pubitemid 28451510)
39. D.R. Zucker, R. Ruthazer, C.H. Schmid, J.M. Feuer, P.A. Fischer, R.I. Kieval, N. Mogavero, R.J. Rapoport, H.P. Selker, S.A. Stotsky, E. Winston, and D.L. Golderberg Lessons learned combining N-of-1 trials to assess fibromyalgia therapies J Rheumatol 33 2006 2069 2077 (Pubitemid 44571885)